DalsnaFinance › Analyst accuracy › JPMorgan › ELVN target
Enliven Therapeutics stock initiated at Overweight by JPMorgan
The target implies 64% upside from the current price of $45.84
A fact about what JPMorgan published, as reported by Investing.com, not a recommendation from Dalsna Finance; JPMorgan is not affiliated with this site.
Full methodology: how targets are collected, scored, ranked and corrected, what each field means, and how to cite the data.